Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary Korn who wrote (748)	12/6/1999 8:53:00 PM
From: William Partmann	Read Replies (1) of 10345

More From Merrill Merrill named Eln the Focus Stock for year 2000 Midcap Pharmaceuticals. Key factor in supporting their recommendation: 1.ELAN'S pipeline is strong and should support earnings per share growth of 25-30 over the next few years. 2. An increased percentage of growth from products that are directly marketed, while financial vehicles are being eliminated, should increase the quality of Eln's earnings. 3.Successful human clinical trials for AN-1792, and other clinical candidate to treat Alzheimer's disease would give eln a pipeline with future sale potential which would dwarf it currently marketed products. price target $45.00. Bill

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next